Trends in the incidence of primary liver cancer in Central Uganda, 1960–1980 and 1991–2005 by Ocama, P et al.
Trends in the incidence of primary liver cancer in Central Uganda,
1960–1980 and 1991–2005
P Ocama*,1, S Nambooze
2, CK Opio
1, MS Shiels
3, HR Wabinga
2 and GD Kirk*,3
1Department of Medicine, Makerere University, PO Box 7072, Kampala, Uganda;
2Department of Pathology, Makerere University, PO Box 7072,
Kampala, Uganda;
3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205, USA
Primary liver cancer (PLC) incidence trends from Africa are unknown. Using Kampala Cancer Registry data from 1960 to 1980 and
1991 to 2005, we identified 771 PLCs. Although rates were stable among men, PLC incidence among women increased 450%.
Investigations of viral hepatitis, aflatoxin, obesity, and human immunodeficiency virus (HIV) may help to explain the increasing
incidence of hepatocellular carcinomas (HCCs).
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Trends in primary liver cancer (PLC) incidence rates will generally
reflect temporal changes in exposure to aetiological agents.
Worldwide, and in sub-Saharan Africa in particular, the great
majority of PLCs are hepatocellular carcinomas (HCCs). In North
America and Europe at present, HCCs are one of the few cancers
observed with increasing incidence (Taylor-Robinson et al, 1997;
El-Serag, 2004; West et al, 2006), largely attributed to earlier
exposure to hepatitis C virus (HCV) (Davila et al, 2004).
Prevalence of obesity and diabetes has also been increasing in
these populations during concurrent time periods and has been
suggested as another possible aetiological factor in rising HCC
rates (Calle et al, 2003; El-Serag et al, 2004).
However, trends in HCC rates from other regions are less clear.
In particular, limited data exist from regions where HCCs is
primarily attributable to chronic hepatitis B viral infection. In
Asia, HCC rates may be declining (Goh, 1997; McGlynn et al,
2001). Reductions in HCC incidence among young children in
Taiwan has been linked to nation-wide hepatitis B vaccination
(Chang et al, 1997). In sub-Saharan Africa, hepatitis B viral
infection is endemic and the attributable fraction of HCCs due to
hepatitis B virus (HBV) is high (B60%) (Kirk et al, 2004; Parkin,
2006). Further, most African countries do not routinely provide or
only recently initiated hepatitis B vaccination as part of their
national immunisation programmes. Urbanisation, obesity, and
HIV infection might also affect HCC rates in Africa. To
characterise temporal trends in HCC rates within an urban African
population, we evaluated cancer registry data collected in Central
Uganda from 1960 through 2005.
MATERIALS AND METHODS
Kampala Cancer Registry
The Kampala Cancer Registry (KCR) was established in the
Department of Pathology, College of Health Sciences, Makerere
University as a population-based cancer registry for Kyadondo
County, Uganda, in 1951. Data were not complete during the
earliest years and registration was halted in the 1980’s because of
political instability. The Kampala Cancer Registry cancer registra-
tion methods have been described earlier (Wabinga et al, 2000).
Briefly, information on demographics, type of cancer (coded using
the second edition of the International Classification of Diseases
for Oncology (Percy et al, 1990)), diagnostic method, and
incidence date for all cancer cases was collected from the major
health units and histopathology laboratories throughout Kyadon-
do County through active and passive methods. Data processing is
done by CANREG, a computerised cancer registration system
(Cooke, 1998) in use since 1989, with entry of earlier manually
collected data. Data from 1960 to 1980 and 1991 to 2005 were
considered complete for the present analyses. Our analysis of de-
identified registry data was not considered human-subjects
research and exempted from IRB review.
Case definitions
On the basis of histology, PLC cases were categorised into HCCs,
non-HCCs, and malignancy not otherwise specified (NOS).
Malignancies NOS (n¼267) accounted for 34% of the cases;
nearly all (94%) were diagnosed clinically without histological
confirmation. Concurrent with increased reliance on ultrasono-
graphy and a-fetoprotein for HCCs clinical confirmation, the
proportion of PLCs histologically confirmed as HCCs declined
recently compared with the earlier time period (86–69% in men;
90–67% in women). To estimate HCC trends appropriately, we
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as HCCs, had histological confirmation been carried out. There-
fore, we calculated the proportion of PLC that were histologically
confirmed HCCs by sex and time period and applied these
proportions to the malignancies NOS; for HCC incidence
estimates, these cases were assumed to be HCCs.
Statistical analysis
The age-standardised incidence rates (ASRs) for PLC and for
HCCs, stratified by sex, were estimated in two broad time periods
(1960–1980 and 1991–2005) and six shorter intervals (1960–1966,
1967–1971, 1972–1980, 1991–1994, 1995–1997, and 1998–2005).
Calendar periods were defined on the basis of a grouping used in
an earlier publication (Wabinga et al, 2000). Substantial popula-
tion growth occurred in Kyadondo County from 268500 residents
in 1960 to 1911720 in 2005; the proportion under 45 years of age
increased slightly from 89.2 to 94.0% during this period. To
calculate incidence rates, annual sex- and age-specific (within
5-year groups) population denominator estimates were interpo-
lated based on the 1959, 1969, 1980, 1991, and 2005 census
estimates, assuming constant growth rates between enumerations
(Wabinga et al, 2000). Incidence rates were standardised to age-
and sex-specific world population estimates for 2000 (US Census
Bureau, 2007). Owing to missing age at diagnosis, 27 cases were
excluded from incidence rate calculations. ASRs and standard
errors were calculated (Boyle and Parkin, 1991) with estimation of
95% confidence intervals (CIs). Incidence rate ratios (IRRs) with
95% CIs were calculated for comparison of rates by calendar
period and gender. Analyses were performed using Microsoft Excel
2003 and Intercooled Stata 8.2 (College Station, TX, USA).
RESULTS
The Kampala Cancer Registry recorded 771 PLCs during the study,
including 261 (33.9%) from 1960 to 1980 and 510 (66.1%) from 1991
to 2005. Among the PLC cases, the median age at diagnosis was 45
years (interquartile range (IQR)¼33, 60; range 1–97) and the male-
to-female ratio was 2.1. Hepatocellular carcinoma was by far the
predominant tumour type, comprising 79% of all histologically
confirmed PLC. Demographic characteristics for PLC and for HCC
were compared across time periods (Table 1). From 1960–1980 to
1991–2005, the median age at histologically confirmed HCC
diagnosis increased slightly from 42 to 44 years. The proportion
of histologically confirmed HCCs diagnosed among women doubled
in the latter period compared with the earlier time period with the
ratio of males to females decreasing (3.9–1.4).
Incidence rates of PLC and HCC among men were relatively
stable from 1960–1980 to 1991–2005 (Table 2). However, among
women, HCC incidence increased 450% during this period
(IRR¼1.56; 95% CI 1.13–2.16). The IRRs comparing men to
women decreased from 2.32 (95% CI 1.70–3.17) in 1960–1980 to
1.30 (95% CI 1.04–1.63) in 1991–2005. Findings for PLC were
similar to those for HCC (Table 2).
When PLC incidence was examined within smaller calendar
periods, trends of increasing HCC rates were observed among both
the sexes, but the increase was substantially more apparent among
women (Figure 1). For both sexes, the greatest increase in PLC
incidence was observed in older age groups (Figure 1), increasing
around twofold among men and fourfold among women aged 45
years or older.
DISCUSSION
In an analysis of cancer registry data compiled over five decades,
we describe PLC and HCC incidence rates in urban Kampala,
Uganda, which are stable among men but increasing among
women. The Kampala Cancer Registry provides population-based
HCC incidence estimates over a much longer time period than
reported earlier from Africa (Bah et al, 2001). Uniquely, these data
allow examination of temporal trends and prompt exploration for
underlying changes in HCC etiological agents to explain observed
changes in incidence.
Although well-controlled studies of HCC etiology in Uganda
have not been carried out, a large proportion will be attributable to
chronic hepatitis B viral infection (Tabor et al, 1977; Parkin, 2006).
In contrast to some Asian HBV-endemic countries where HCC
incidence rates may be declining (Goh, 1997; McGlynn et al, 2001),
our data suggest that HCC rates are increasing in Uganda. National
estimates of chronic HBV prevalence in Ugandan adults is 9%
Table 1 Demographic characteristics of primary liver cancers and
histologically confirmed hepatocellular carcinoma cases in the Kampala
Cancer Registry, Kyadondo County, Uganda: 1960–1980 and 1991–2005
Primary liver
cancer cases
Hepatocellular
carcinoma cases
Time period 1960–1980 1991–2005 1960–1980 1991–2005
N (%) 261 510 201 120
Median age (IQR)
a 42 (32, 55) 48 (33, 61) 42 (34, 53) 44 (30, 54)
Sex (%)
Male 205 (79%) 296 (58%) 160 (80%) 69 (58%)
Female 56 (21%) 214 (42%) 41 (20%) 51 (43%)
Male:female ratio 3.7 1.4 3.9 1.4
aIQR¼interquartile range.
Table 2 Age-standardised incidence rates for primary liver cancer (PLC) and hepatocellular carcinoma (HCC) by gender in Kyadondo County, Uganda:
1960–1980 and 1991–2005
1960–1980 1991–2005
N ASRs
a 95% CIs N ASRs 95% CIs IRR:recent to early period 95% CIs
PLC
Males 195 6.96 5.88–8.04 288 7.13 6.17–8.09 1.02 0.83–1.26
Females 53 2.93 2.09–3.77 208 5.33 4.51–6.15 1.82 1.36–2.44
IRR:males to females 2.38 1.77–3.19 1.34 1.09–1.64
HCC
Males 173 6.15 5.13–7.17 218 5.38 4.55–6.20 0.87 0.71–1.08
Females 49 2.65 1.85–3.44 156 4.14 3.42–4.86 1.56 1.13–2.16
IRR:males to females 2.32 1.70–3.17 1.30 1.04–1.63
aASRs¼age-standardised incidence rates, calculated per 100000 person-years; CIs¼confidence intervals; IRR¼incidence rate ratio.
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(Sadikali, 1972; Tabor et al, 1977; de Lalla et al, 1990) to the more
recent ones (Nakwagala and Kagimu, 2002; Pido and Kagimu,
2005), no compelling evidence exists that HBV prevalence has
changed substantively in Uganda. Notably, the male-to-female
ratio in HBV-related HCCs would be expected to increase rather
than decrease as we observed. Importantly, Uganda incorporated
childhood vaccination against hepatitis B into their national
immunisation programme in 2002, so any impact of this highly
effective preventive intervention on HCC rates will not likely be
observable for years.
Although increasing HCC rates in Europe and North America
are largely attributed to HCV, chronic HCV infection is very
uncommon in Uganda (Hladik et al, 2006). Chronic HCV infection
with viremia is rare even in high-risk persons (Jackson et al, 1991;
Biggar et al, 2006). Although it is unlikely that HCV would fully
explain the increasing HCC rates, further evaluation is warranted,
particularly because PLC increases among older Ugandans are
consistent with an HCV cohort effect reported from other sub-
Saharan African populations (Kirk et al, 2006).
Dietary exposure to aflatoxin is a well-recognised cause of HCC,
including an early report from Uganda (Alpert et al, 1971).
Although a variety of Ugandan foods may be contaminated with
aflatoxin (Kaaya and Kyamuhangire, 2006), human exposures have
not been assessed. Rural to urban migrants in South Africa
retained higher HCC risk, attributed in part to greater aflatoxin
exposure (Kew et al, 1983; Kimbi et al, 2005). During recent
decades, Kampala has been dramatically shaped by a large influx of
persons migrating from rural areas.
Recent data have linked obesity and diabetes to HCC develop-
ment (Calle et al, 2003; El-Serag et al, 2004; Larsson and Wolk,
2007). In Uganda, reliable population data on changes in obesity
are sparse. However, in light of the relative increase in HCC among
women, it is interesting to note that Ugandan women were more
likely to show the association between overweight and type 2
diabetes than the generally leaner men (Lasky et al, 2002).
Data are limited on the prevalence or trends of other factors
potentially influencing HCC rates. Per capita alcohol consumption in
Uganda is among the highest in the world (WHO, 2004). Anecdotal
evidence suggests that drinking alcohol and cigarette smoking by
women have become more acceptable and increased in Uganda
during recent years. Reduced parity is associated with increasing
HCC risk among women (Yu et al, 2003). According to the United
Nations Population Division data, total fertility rates in Uganda
appear to have been stable from 1970 to 1990, with subsequent small
annual declines of around 0.5% from 1990 to 2006.
The major demographic and health impact occurring in Uganda
between 1960 and 2005 has clearly been the human immuno-
deficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)
epidemic. Although HIV will accelerate HBV or HCV disease
progression, HIV-infected persons rarely survive long enough to
manifest HCC in the absence of highly active antiretroviral therapy
(HAART). Owing to the competing risks of AIDS, studies in the
United States failed to show HCC increases among HIV-infected
persons through the early HAART years (Mbulaiteye et al, 2003;
Kramer et al, 2005). However, recent studies with longer follow-up
have documented significant increases in liver disease (Bica et al,
2001; Salmon-Ceron et al, 2005) and suggested HCC increases
(Clifford et al, 2005; Powles et al, 2006). Similar to pre-HAART
data from developed countries, earlier Ugandan studies have not
shown an increased HCC risk associated with HIV (Wabinga et al,
2000; Mbulaiteye et al, 2006). HAART was introduced in Uganda in
2003–2004; therefore, neither those earlier studies nor the current
analysis would reflect HAART effects. Our evidence that HCC rates
appear to be increasing before any observable HAART-related
effect raises considerable concern that the burden of HCCs may
expand substantially in future years (Powles et al, 2006).
Limitations of cancer registry data collected in a resource-
limited settings have been discussed in detail earlier (Wabinga
et al, 2000). In brief, the completeness of KCR cancer registration
was formally estimated at 93% for HCC cases (Parkin et al, 2001).
However, observed HCC rates were lower than in some other HBV-
endemic regions, suggesting possible under-ascertainment. We did
observe temporal changes in HCC diagnostic methods with
decreased reliance on liver biopsy. However, in HBV-endemic
regions the HCC case definition utilising clinical criteria, ultra-
sound, and a-fetoprotein has high predictive accuracy and
excellent specificity (Ho and Johnson, 1999). Although concerns
regarding the accuracy of population denominator estimates
interpolated from periodic census enumerations can be raised, it
seems unlikely that estimates would have been differential by
gender to account for the observed sex differences.
In conclusion, we present long-term cancer registry data from
Uganda suggesting stable HCC incidence among men with increasing
rates among women. With the potential for increasing HCC rates
after prolonged survival of effectively treated HIV-infected persons,
continued HCC surveillance will be vital to monitor trends.
Irrespective of gender, HCCs present at very advanced stages and
are highly lethal (Gondos et al, 2005). Therefore, systematic
investigation of HCC etiological factors in Uganda is needed to
inform appropriate primary preventive interventions (e.g., hepatitis
B vaccine, aflatoxin reduction programmes, dietary, or physical
activity interventions to prevent obesity).
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Figure 1 Age-standardised incidence rates of primary liver cancer
among men (A) and women (B) overall, and stratified by age 45 years and
older in Kyadondo County, Uganda: 1960–2005. Bars represent 95%
confidence intervals, calculated using a natural logarithmic transformation,
around each estimate.
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